Banque Pictet & Cie SA Has $5.35 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Banque Pictet & Cie SA lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,986 shares of the biotechnology company's stock after selling 4,059 shares during the quarter. Banque Pictet & Cie SA's holdings in Sarepta Therapeutics were worth $5,348,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. MassMutual Private Wealth & Trust FSB raised its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. raised its stake in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the period. Huntington National Bank raised its stake in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $36,000. Finally, Values First Advisors Inc. bought a new stake in Sarepta Therapeutics in the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT traded down $2.60 during trading hours on Tuesday, hitting $105.35. The company's stock had a trading volume of 1,298,770 shares, compared to its average volume of 805,629. The stock has a fifty day simple moving average of $119.00 and a 200-day simple moving average of $124.34. The company has a market capitalization of $10.06 billion, a P/E ratio of 84.28 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a twelve month low of $101.15 and a twelve month high of $173.25.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on SRPT shares. StockNews.com cut Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price objective on the stock. Royal Bank of Canada reiterated an "outperform" rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Finally, Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a "buy" rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $176.77.

Insider Activity at Sarepta Therapeutics

In other news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.